Drug
Ipragliflozin
Ipragliflozin: highest development phase Phase 3, developed by Astellas, Merck. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Astellas, Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| ipragliflozin NCT01316107 | Phase 3 | Type 2 Diabetes Mellitus |
| Ipragliflozin NCT02577003 | Phase 3 | Type 2 Diabetes Mellitus |
| Ipragliflozin NCT01611428 | Phase 1 | Bioavailability of Ipragliflozin |
Latest
No recent events.
Follow Ipragliflozin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.